SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — John Locke Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJohn Locke
Date of birth1632-09-08
IdentifiersMRN HR-EN001-SYN-TD; SSN (made up) 000-01-8305
Document date2026-11-01
AuthorPrudence Hartwell-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care visit for a lifelong cough with wheeze and breathlessness, worse in city air and by open fires, in a never-smoker. Concerns: He has coughed for twenty years, and the city air leaves him unable to breathe; he wants to be able to do his work there; He wonders whether this is the consumption that his father and brother had; He asks whether the fire in his study is part of the problem. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometryTwo puffs every 4 hours as neededRespiratory tract route1692-03-12 to 1692-03-26completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayTwo inhalations twice daily plus one as needed; no more than 12 a dayRespiratory tract route1692-03-26activeS
Tiotropium 2.5 mcg/actuation soft-mist inhaler, two inhalations once daily (add-on long-acting muscarinic antagonist, GINA step 5)Two inhalations once a dayRespiratory tract route1692-06-18activeS
Acetaminophen 500 mg oral tablet, one or two tablets every 6 hours as needed for aches or fever, no more than 3 g a dayOne or two tablets every 6 hours as needed; no more than six tablets a dayOral route1692-10-08 to 1692-10-22completedS

Procedures

ProcedureDatesStatusEvidence
Chest X-ray, posteroanterior and lateral: mild hyperinflation; normal heart size; no consolidation, mass, cavitation, hilar enlargement, or effusion1692-03-12 to 1692-03-12completedS
CT of the chest without contrast, with expiratory images: diffuse bronchial wall thickening and mosaic attenuation with air trapping on expiration; no emphysema, bronchiectasis, nodules, lymph node enlargement, or interstitial lung disease1692-03-26 to 1692-03-26completedS

Immunizations

DateVaccineStatusEvidence
1687-05-10Tdap vaccinecompletedS
1691-10-14Influenza vaccine, last seasoncompletedS
1692-03-26Pneumococcal conjugate vaccine PCV20completedS
1692-09-17Influenza vaccine, 1692-1693 seasoncompletedS
1692-09-17COVID-19 mRNA vaccine, this season's formulacompletedS
1692-09-17Respiratory syncytial virus vaccine, single dosecompletedS
1692-10-22Recombinant zoster vaccine, dose 1 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
About 1670A cough that began about the age of 38 and troubled him thereafter, by his biographer's accountD (CLM-0006)
From 1679Unable to stay long in London because of its coal smoke, and away from the city every winterD (CLM-0007)
1691 to 1692Moved to the country because the smoke of London harmed his health; wrote that his lungs could not bear the smoke of the cityD (CLM-0010, CLM-0011)

Family History

RelativeConditionAge at deathEvidence
fatherDied at about 54 of consumption or some kindred malady, by his biographer's accountD (CLM-0003)
brotherDied of consumption at about 26, by his biographer's accountD (CLM-0003)

Health Concerns

ConcernStatusEvidence
He has coughed for twenty years, and the city air leaves him unable to breathe; he wants to be able to do his work thereactiveS
He wonders whether this is the consumption that his father and brother hadactiveS
He asks whether the fire in his study is part of the problemactiveS

Assessment

Most recent measures: Total score [ACT] 21 on 1692-10-22; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1692-09-17; Hemoglobin [Mass/volume] in Blood 14.8 on 1692-03-12; Leukocytes [#/volume] in Blood by Automated count 7.4 on 1692-03-12; Eosinophils [#/volume] in Blood by Automated count 0.46 on 1692-03-12; Platelets [#/volume] in Blood by Automated count 251 on 1692-03-12; IgE [Units/volume] in Serum or Plasma 186 on 1692-03-12; Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma 131 on 1692-03-12; Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 58 on 1692-03-12; Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood 0.02 on 1692-03-12; FEV1 --pre bronchodilation 2.46 on 1692-06-18; Forced vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation 3.71 on 1692-03-26; FEV1/FVC 0.57 on 1692-03-26; FEV1 measured/predicted 73 on 1692-06-18; FEV1 --post bronchodilation 2.58 on 1692-06-18; Forced vital capacity [Volume] Respiratory system --post bronchodilation 4.12 on 1692-06-18; FEV1/FVC --post bronchodilation 0.63 on 1692-06-18; Diffusion capacity.carbon monoxide 26.4 on 1692-03-26; Fractional concentration of exhaled nitric oxide 22 on 1692-06-18; Six minute walk test 505 on 1692-06-18; Cholesterol [Mass/volume] in Serum or Plasma 182 on 1692-09-17; Cholesterol in HDL [Mass/volume] in Serum or Plasma 64 on 1692-09-17; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 101 on 1692-09-17; Triglyceride [Mass/volume] in Serum or Plasma 85 on 1692-09-17; Maximum expiratory gas flow Respiratory system airway by Peak flow meter 430 on 1692-10-22 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluationresolvedconfirmed R05.3S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit.
Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at homeactiveconfirmed Z77.110S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted.
Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPDactiveconfirmed J45.40S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R).
Acute viral upper respiratory infection (common cold) with a yellow-zone asthma flare: peak flow 68 percent of personal best, managed with extra as-needed budesonide-formoterol by his action plan, without oral corticosteroids; resolvedresolvedconfirmed J06.9S — Synthetic intercurrent illness at an unscheduled visit; it echoes, without asserting, his documented autumn chest troubles (CLM-0014).

Results

DateMeasureValueUnitReference rangeFlagProvenance
1692-03-12Total score [ACT]12{score}S
1692-03-12Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1692-03-12Hemoglobin [Mass/volume] in Blood14.8g/dL13.2-16.6 g/dLNormalS
1692-03-12Leukocytes [#/volume] in Blood by Automated count7.410*3/uL3.4-9.6 10*3/uLNormalS
1692-03-12Eosinophils [#/volume] in Blood by Automated count0.4610*3/uL0.15 or more suggests type 2 airway inflammation; 0.30 or more is typical of itNormalS
1692-03-12Platelets [#/volume] in Blood by Automated count25110*3/uL150-400 10*3/uLNormalS
1692-03-12IgE [Units/volume] in Serum or Plasma186[IU]/mL<=100 [IU]/mLHighS
1692-03-12Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma131mg/dL90-200 mg/dLNormalS
1692-03-12Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma58pg/mLBelow 125 pg/mL makes heart failure unlikely in an outpatientNormalS
1692-03-12Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ T-cells [Units/volume] corrected for background in Blood0.02[IU]/mLPositive at 0.35 IU/mL or moreNormalS
1692-03-26FEV1 --pre bronchodilation2.11LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
1692-03-26Forced vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation3.71LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 LNormalS
1692-03-26FEV1/FVC0.57{ratio}Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cmLowS
1692-03-26FEV1 measured/predicted62%GLI Global race-neutral equations for a man of 59, 178 cmLowS
1692-03-26FEV1 --post bronchodilation2.49LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
1692-03-26Forced vital capacity [Volume] Respiratory system --post bronchodilation4.02LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 LNormalS
1692-03-26FEV1/FVC --post bronchodilation0.62{ratio}Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitationLowS
1692-03-26Diffusion capacity.carbon monoxide26.4mL/min/mm[Hg]Lower limit of normal, GLI 1683 race-neutral equations; predicted 26.9NormalS
1692-03-26Fractional concentration of exhaled nitric oxide41[ppb]In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS)HighS
1692-03-26Six minute walk test430mPredicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 mLowS
1692-03-26Total score [ACT]13{score}S
1692-06-18Total score [ACT]19{score}S
1692-06-18FEV1 --pre bronchodilation2.46LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
1692-06-18FEV1 measured/predicted73%GLI Global race-neutral equations for a man of 59, 178 cmLowS
1692-06-18FEV1 --post bronchodilation2.58LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
1692-06-18Forced vital capacity [Volume] Respiratory system --post bronchodilation4.12LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 LNormalS
1692-06-18FEV1/FVC --post bronchodilation0.63{ratio}Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitationLowS
1692-06-18Fractional concentration of exhaled nitric oxide22[ppb]In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS)NormalS
1692-06-18Six minute walk test505mPredicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 mNormalS
1692-09-17Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1692-09-17Cholesterol [Mass/volume] in Serum or Plasma182mg/dL<=199 mg/dLNormalS
1692-09-17Cholesterol in HDL [Mass/volume] in Serum or Plasma64mg/dL>=40 mg/dLNormalS
1692-09-17Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation101mg/dL<=129 mg/dLNormalS
1692-09-17Triglyceride [Mass/volume] in Serum or Plasma85mg/dL<=149 mg/dLNormalS
1692-10-08Maximum expiratory gas flow Respiratory system airway by Peak flow meter300L/min80 percent of his personal best of 440 L/minLowS
1692-10-22Maximum expiratory gas flow Respiratory system airway by Peak flow meter430L/min80 percent of his personal best of 440 L/minNormalS
1692-10-22Total score [ACT]21{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1692-03-12Body height178cmS
1692-03-12Body weight62kgS
1692-03-12Body mass index (BMI) [Ratio]19.6kg/m2S
1692-03-12Systolic blood pressure122mm[Hg]S
1692-03-12Diastolic blood pressure74mm[Hg]S
1692-03-12Heart rate84/minS
1692-03-12Respiratory rate18/minS
1692-03-12Body temperature36.6CelS
1692-03-12Oxygen saturation in Arterial blood by Pulse oximetry95%S
1692-03-26Body height178cmS
1692-03-26Body weight62.1kgS
1692-03-26Body mass index (BMI) [Ratio]19.6kg/m2S
1692-03-26Systolic blood pressure120mm[Hg]S
1692-03-26Diastolic blood pressure74mm[Hg]S
1692-03-26Heart rate82/minS
1692-03-26Respiratory rate18/minS
1692-03-26Body temperature36.5CelS
1692-03-26Oxygen saturation in Arterial blood by Pulse oximetry95%S
1692-06-18Body height178cmS
1692-06-18Body weight62.8kgS
1692-06-18Body mass index (BMI) [Ratio]19.8kg/m2S
1692-06-18Systolic blood pressure118mm[Hg]S
1692-06-18Diastolic blood pressure72mm[Hg]S
1692-06-18Heart rate76/minS
1692-06-18Respiratory rate16/minS
1692-06-18Body temperature36.6CelS
1692-06-18Oxygen saturation in Arterial blood by Pulse oximetry97%S
1692-09-17Body height178cmS
1692-09-17Body weight63kgS
1692-09-17Body mass index (BMI) [Ratio]19.9kg/m2S
1692-09-17Systolic blood pressure120mm[Hg]S
1692-09-17Diastolic blood pressure74mm[Hg]S
1692-09-17Heart rate74/minS
1692-09-17Respiratory rate16/minS
1692-09-17Body temperature36.6CelS
1692-09-17Oxygen saturation in Arterial blood by Pulse oximetry97%S
1692-10-08Body height178cmS
1692-10-08Body weight62.6kgS
1692-10-08Body mass index (BMI) [Ratio]19.8kg/m2S
1692-10-08Systolic blood pressure124mm[Hg]S
1692-10-08Diastolic blood pressure76mm[Hg]S
1692-10-08Heart rate94/minS
1692-10-08Respiratory rate20/minS
1692-10-08Body temperature37.6CelS
1692-10-08Oxygen saturation in Arterial blood by Pulse oximetry95%S
1692-10-22Body height178cmS
1692-10-22Body weight62.8kgS
1692-10-22Body mass index (BMI) [Ratio]19.8kg/m2S
1692-10-22Systolic blood pressure118mm[Hg]S
1692-10-22Diastolic blood pressure72mm[Hg]S
1692-10-22Heart rate74/minS
1692-10-22Respiratory rate16/minS
1692-10-22Body temperature36.5CelS
1692-10-22Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
1692-03-12Primary care visit for a lifelong cough with wheeze and breathlessness, worse in city air and by open fires, in a never-smokerfinishedS
1692-03-26Two-week review of lung function and blood tests, diagnosis, start of treatment, and pulmonology consultationfinishedS
1692-06-18Twelve-week asthma review with repeat spirometry after pulmonary rehabilitationfinishedS
1692-10-22Asthma review two weeks after a cold with a yellow-zone flarefinishedS
1692-09-17Preventive health visit at 60finishedS
1692-10-08Same-day sick visit for a cold with a yellow-zone asthma flarefinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Diagnostic workup: spirometry before and after bronchodilator, FeNO, DLCO, blood count with eosinophils, total IgE, alpha-1 antitrypsin, NT-proBNP, interferon-gamma release assay, chest X-ray, and CT of the chest if airflow limitation persists after bronchodilator; albuterol withheld for 6 hours before testingcompletedGL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020, GL-GOLD-2025, GL-ATS-ERS-PFT-2022, GL-ATS-RACE-2023S
Exposure reduction from today: no open coal or wood fires in his rooms (electric or heat-pump heating instead); a portable HEPA air cleaner sized for his study and bedroom; daily check of the air quality index, with city trips and outdoor exertion avoided on alert days; a well-fitted N95 respirator on unavoidable high-pollution days; quieter routes away from main roadscompletedGL-WHO-AQG-2021, GL-ERS-AIR-2020, GL-AIRNOW-AQI, GL-EPA-AIRCLEAN, GL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020S
Pulmonology consultation on the diagnosis (asthma, COPD, or both), the need for CT, treatment, and pulmonary rehabilitationcompletedGL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020, GL-GOLD-2025S
Shared decision on treatment: budesonide-formoterol 160/4.5 mcg as maintenance and reliever, two inhalations twice daily plus one as needed, no more than 12 a day; albuterol stopped; inhaler technique taught and checked at every visit; a written asthma action plancompletedGL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020S
Pulmonary rehabilitation: an eight-week, twice-weekly program of supervised exercise training and education, with a six-minute walk test before and aftercompletedGL-GINA-2025, GL-CMID-2026, GL-ATS-PR-2023S
Vaccinations: pneumococcal conjugate vaccine PCV20 at the diagnosis visit; influenza, COVID-19, and RSV vaccines in the autumn; recombinant zoster vaccinecompletedGL-CDC-IMZ-2026, GL-CMID-2026S
Monitoring: Asthma Control Test, inhaler technique, adherence, reliever use, and exposures at every visit; spirometry and FeNO 3 months after starting treatment, then every 1 to 2 years; home peak flow diarycompletedGL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020S
Add-on tiotropium 2.5 mcg soft-mist inhaler, two inhalations once daily, for persistent symptoms and airflow limitation on medium-dose budesonide-formoterol; written action plan updated with peak-flow zones from his personal best of 440 L/mincompletedGL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020S
After any flare: a review within one week, booked by the clinic when he calls or is seen for the flarecompletedGL-CMID-2026, GL-GINA-2025, GL-NAEPP-2020S

Goals

GoalTargetStatusOutcomeProvenance
Cause of the cough and breathlessness established by the second visit1692-03-26completedAsthma with persistent airflow limitation confirmed by spirometry, FeNO, eosinophils, DLCO, and CT; tuberculosis, alpha-1 antitrypsin deficiency, and heart failure excludedS
Asthma well controlled (Asthma Control Test 20 or more) with no flare needing oral corticosteroids1693-03-31activeACT 21 at the last visit; one yellow-zone flare with a cold, managed by the action plan without oral corticosteroidsS
No indoor solid-fuel smoke and less outdoor pollution exposure1693-03-31activeOpen fires out of use since intake; HEPA air cleaner in his study and bedroom; air quality alerts followedS
Six-minute walk distance improved by at least 30 m after pulmonary rehabilitation1692-06-18completed430 m before and 505 m after an eight-week programS

Functional Status

Mental Status